Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and in vitro.

Journal of Neural Transmission
Richard T Reid, Marwan N Sabbagh

Abstract

Cholinesterase inhibitors (ChEIs) are the mainstay of treatment for AD but differ by secondary mechanisms of action. We determine the effects of sub-chronic dosing of ChEIs on alpha7 and non-alpha7 nAChRs and determine if differences can be observed between them. Sprague-Dawley rats were administered donepezil, galantamine; rivastigmine at two doses each, in saline SQ twice daily or with nicotine (0.4 mg/kg) as a positive control. After 14 days the animals were sacrificed, and the levels of nAChRs were measured using [3H]-EPI to measure non-alpha7 nAChRs and [3H]-MLA to measure alpha7 nAChRs. In the cortex, all compounds tested at the higher doses significantly increased the levels of both [3H]-EPI and [3H]-MLA. In the hippocampus all compounds significantly increased [3H]-EPI but had no effect on [3H]-MLA binding. No effects were observed in the striatum with treatment. There were no differences observed among the ChEIs. In cell cultures, none of the ChEIs increased non-alpha7 or alpha7 receptor binding. Treatment with ChEIs result in similar increases in receptor levels which suggest that the increases in nAChRs may be due simply to the increases in synaptic levels of acetylcholine.

References

Jan 1, 1992·Journal of Neuroscience Research·A NordbergB Winblad
Nov 1, 1990·Journal of Neuroscience Research·K SugayaV A Chiappinelli
Jan 1, 1990·Journal of Neural Transmission. Parkinson's Disease and Dementia Section·E K PerryR H Perry
Sep 21, 1990·European Journal of Pharmacology·L Nilsson-HåkanssonA Nordberg
Jul 1, 1994·Neurochemistry International·A Nordberg
Nov 24, 1998·Journal of Neural Transmission·M N SabbaghL J Thal
Feb 15, 2001·Proceedings of the National Academy of Sciences of the United States of America·D S Woodruff-PakG L Wenk
Mar 7, 2001·Biological Psychiatry·S Shimohama, T Kihara
Mar 23, 2001·Acta Neurologica Scandinavica. Supplementum·M SamochockiA Maelicke
Mar 29, 2001·Proceedings of the National Academy of Sciences of the United States of America·Q LiuD K Berg
Jul 31, 2003·Biochemical Society Transactions·N S Millar
Feb 6, 2004·Journal of Alzheimer's Disease : JAD·Richard T Reid, Marwan N Sabbagh
Mar 1, 2005·European Journal of Pharmacology·Chantal J G M SmuldersHenk P M Vijverberg
Aug 2, 2005·Journal of Molecular Neuroscience : MN·Patricia W LambJerrel L Yakel
Jan 7, 2006·The Journal of Pharmacology and Experimental Therapeutics·Tangui MauriceDaniel T Monaghan
Jun 15, 2006·Alzheimer Disease and Associated Disorders·Agneta Nordberg

❮ Previous
Next ❯

Citations

May 9, 2013·Pharmacology, Biochemistry, and Behavior·Nichole M NeugebauerMarina R Picciotto
Jun 22, 2010·CNS Neuroscience & Therapeutics·Alessandro MartoranaGiacomo Koch
Nov 14, 2017·Neurorehabilitation and Neural Repair·Patricia B de la TremblayeAnthony E Kline
Oct 10, 2020·Neuropharmacology·Gabriella MarucciFrancesco Amenta

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Forebrain- Circuits

Basal forebrain is a region in the brain important for production of acetylcholine and is the major cholinergic output of the CNS. Discover the latest research on circuits in the basal forebrain here.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Related Papers

International Journal of Alzheimer's Disease
Mona MehtaMarwan N Sabbagh
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Björn SchilströmTorgny H Svensson
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco
Jill R TurnerJulie A Blendy
© 2022 Meta ULC. All rights reserved